Value, Pricing & Access Strategy.

Meet the needs of payers, clinicians, and patients.

See our full suite of Value, Pricing & Access services

What we do.

Meet the needs of payers, clinicians and patients with value-driven pricing and market access strategies that deliver access for patients and recognize your organization for its innovation.

We transcend commercial and scientific domains to provide payer landscape and opportunity assessment, strategic value propositions, evidence gap assessment and evidence generation plans, HTA navigation, payer and channel contracting, distribution strategy and beyond.

How we help.

We can help you assess access opportunities and challenges and pursue value-based pricing and quality access across all stages of product development and lifecycle.

We provide true strategic partnership with a relentless focus on your business objectives, leveraging our depth of scientific and commercial expertise, a cross-functional collaborative approach, and agile attitude.

Learn about our Centers of Excellence

Our world-class Value, Pricing, and Access strategy team provides a holistic set of consultative solutions, including:

Strategic market access planning and roadmaps
Pricing strategy and TPP evaluation
Landscape analysis
Opportunity assessment
HTA strategy and submission support
Strategic value proposition testing
Evidence gap analysis and generation plans
Tactical value communications
Offer, tender, and contracting strategy
Negotiation guides and playbooks
Distribution and access services planning
Patient out-of-pocket cost and access optimization
Loss-of-exclusivity strategy

Featured case study

Early value insights to drive value definition and evidence needs to produce TrPP.

We developed recommendations for our pharmaceutical client looking to understand the key drivers of value for a new treatment across major global markets and the evidence required to support these value drivers.

View all case studies

Featured

Early value insights to drive value definition and evidence needs to produce TrPP

A large multinational pharmaceutical player is developing a new therapy for sleep disorders including narcolepsy. The overarching goal of the work...

Michael Lees

Partner, Market Access and Putnam PHMR Operations Lead

Read bio

Ryan Wyrtzen

Partner

Read bio

Joanne Evason

Partner

Read bio

Clement Francois

Partner, HTA and Market Access Operations

Read bio

Alexander Busch

Partner

Read bio

Latest thinking.

Get the latest insights and perspectives from our experts.

View all of our resources

Webinar on the IRA in partnership with BioCentury

Scott Briggs, Principal, joined a live panel of industry experts to discuss the Inflation Reduction Act on March 30th.

Early value insights to drive value definition and evidence needs to produce TrPP

A large multinational pharmaceutical player is developing a new therapy for sleep disorders including narcolepsy. The overarching goal of the work...

The burden of hospitalizations for COVID-19 in France: A study of all cases in the national insurance claims database in 2020

Our Putnam PHMR colleagues delivered an in-depth analysis on the burden of patient hospitalizations in France as a result of COVID-19. The study...

HTA evidence generation and preparedness for a novel oncology treatment

Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment...

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Related offerings.